close

Agreements

1 229 230 231 232 233 246
Number of results: 4911

PDF print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2011-10-28 Topotarget (Denmark) Multimeric Biotherapeutics (USA) multimeric TNF superfamily ligands (TNFSFs)

licensing

Licensing agreement
2011-10-28 Protagen (Germany) Charles River (USA) protein analytics from detailed protein characterization to stability and lot release testing

commercialisation

Commercialisation agreement
2011-10-28 Atlab Pharma (France) BZL Biologics (USA) 177Lu-J591

licensing

Cancer - Oncology Licensing agreement
2011-10-27 Oncodesign (France) Taconic (USA) pre-clinical oncology in vivo solutions for researchers

development
promotion

Cancer - Oncology Establishment of a new subsidiary in the EU
2011-10-26 Sanofi (France) Immune Design Corp (USA) Glucopyranosyl Lipid Adjuvant (GLA) technology allergy

R&D

Allergic diseases - Immunological diseases R&D agreement
2011-10-25 Lonza (Switzerland) Genmab (Denmark) HuMax-TF® \

development
manufacturing
production

 

Cancer Oncology Production agreement
2011-10-25 Probiogen (Germany) Inhibrx (USA) GlymaxX® Antibody Glyco-Engineering technology

licensing

Licensing agreement
2011-10-24 Encap Drug Delivery (UK) Lena Nanoceutics (UK) drug delivery technology (Nano-Capsules) combining nano-particle engineering technology with liquid filled hard capsule technology

development

Development agreement
2011-10-24 Silence Therapeutics (UK) Mirna Therapeutics (USA) novel microRNAs candidate drugs based on AtuPLEX™ and DBTC delivery systems undisclosed

R&D
collaboration

R&D agreement
2011-10-20 Ipsen (France) Syntaxin (UK) botulinum toxins research - R&D - development - commercialisation R&D agreement
2011-10-20 Evotec (Germany) Apeiron Biologics (Austria) active molecules interacting with Cbl-b target research - R&D Cancer - Oncology R&D agreement
2011-10-18 Flamel Technologies (France) GSK (UK) Coreg CR® microparticles supply
2011-10-17 Angel Biotechnology (UK) Materia Medica Holding (Russia)

joint-venture

manufacturing

production

Production agreement
2011-10-17 Agilent Technologies (USA) Oxford Gene Technology (UK) oligonucleotide microarrays and SureSelect target enrichment products for next-generation sequencing Collaboration agreement
2011-10-13 Eagle Pharmaceuticals (USA) Flamel Technologies (France) Medusa-based hydrogel depot formulation of tigecycline

development
licensing

Infectious diseases Development agreement
2011-10-12 Galapagos (Belgium) Chiesi (Italy) research - R&D R&D agreement
2011-10-12 Bayer HealthCare (Germany) Onyx Pharmaceuticals (USA) Nexavar® (sorafenib) and regorafenib liver cancer, advanced kidney cancer, hepatocellular carcinoma, advanced renal cell carcinoma

development
commercialisation

Cancer - Oncology Development agreement
2011-10-12 deCODE genetics (Iceland) Pfizer (USA - NY) variants in the human genome that confer risk of systemic lupus erythematosis. systemic lupus erythematosis

R&D

Autoimmune diseases R&D agreement
2011-10-12 Faron Pharmaceuticals (Finland) Biovian (Finland) humanized anti-Clever-1 antibody FP-1304

development
manufacturing
production

Cancer - Oncology Development agreement
2011-10-11 Karyopharm Therapeutics (USA) Katholieke Universiteit Leuven (Belgium) Selective Inhibitors of Nuclear Export (SINE) modulators of the CRM1 protein cancer, autoimmune diseases and viral diseases research - R&D Cancer - Oncology - Autoimmune diseases - Infectious diseases R&D agreement